174
Participants
Start Date
August 12, 2014
Primary Completion Date
July 14, 2017
Study Completion Date
August 18, 2019
MOXR0916
MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
Institut Jules Bordet, Brussels
Chris O'Brien Lifehouse, Camperdown
Sint Augustinus Wilrijk, Wilrijk
Peter Maccallum Cancer Centre, Melbourne
Austin Hospital, Heidelberg
Sir Charles Gairdner Hospital, Nedlands
UZ Gent, Ghent
Memorial Sloan-Kettering Cancer Center, New York
Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Hosp de Madrid Norte Sanchinarro; Centro Integral; Onco Clara Campal, Madrid
Clinica Universitaria de Navarra, Pamplona
Sarah Cannon Research Institute, Nashville
Hospital Clinico Universitario de Valencia, Valencia
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago
HonorHealth Research Institute - Bisgrove, Scottsdale
Seattle Cancer Care Alliance, Seattle
University of Colorado, Aurora
Yale School of Medicine, New Haven
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Can Ins, Boston
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver
Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton
The Ottawa Hospital Cancer Centre; Oncology, Ottawa
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal
Seoul National University Hospital, Seoul
Asan Medical Center - Oncology, Seoul
Yonsei University Health System/Severance Hospital, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Genentech, Inc.
INDUSTRY